Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cadus Pharmaceutical Corp. (KDUS) -- Ignore unavailable to you. Want to Upgrade?

To: David Richardson who wrote (126)	3/10/2000 12:49:00 PM
From: tuck	Read Replies (3) \| Respond to of 1833

Richard, This is an interesting situation. Three things get my attention with this one: 1) Carl owns 25% of the stock but has ties with nearly half the BOD. Not sure what the implications of that are. 2) Company 10-K mentions other competitors doing one thing or another with yeast-based genomics, but doesn't choose to enlighten us as to who those competitors might be. Do you know of any? I gather management believes Cadus is the only one with an entire platform technology, a complete drug discovery system, based on yeast. 3) How big a deal is this litigation, anyhow? Seems to me they are close to working around the patented technology problem. If they win the dispute, they can sue for the damages that arose from being jammed up like this. Seems to me the worst is priced in, but neither will the stock see double digits until a) the patent dispute is resolved and Cadus either wins or licenses, or b) Cadus announces they can do the readout another way. Interested in your thoughts about the above. Cheers, Tuck

To: David Richardson who wrote (126)	3/25/2000 5:00:00 PM
From: scaram(o)uche	Respond to of 1833

Dave: >> He didn't seem to think that these legal problems were going to get straightened out any time soon. << My valuation is largely based on time-discounted royalty flow. While I hope that Merck will just fold in response to the Office action, I'm not holding my breath. But, my opinion...... bargain without the escrow cash, and some protection on the downside. That's the way I like them. >> When he left Cadus his stock options were under the water << That stinks. Too bad that prior management didn't have more respect for claim language and the amount of time and $$$$ required to revise such wording. Cheers! Rick